Literature DB >> 24574366

Overenthusiastic stroke risk factor modification in the over-80s: are we being disingenuous to ourselves, and to our oldest patients?

Kit Byatt1.   

Abstract

Statins and antihypertensive therapy are widely used in our oldest patients (ie, those aged over 80 years). The epidemiology suggests that, by this age, hypertension is not an attributable risk factor for stroke, and hypercholesterolaemia has little effect on stroke risk overall. The largest trials of antihypertensive therapy and statins in this age group show at best a marginal clinical reduction in stroke and very modest clinical reductions in other cardiovascular end points. Older patients have very diverse views on the relative importance of stroke and death as end points, and these differ from physicians' views. Informed consent principles (full relevant information in an accessible form, and autonomy of decision-making) suggest that these medications are greatly over-prescribed in the healthy elderly and largely irrelevant in the frail elderly, but require that the patient should be actively involved in the process.

Entities:  

Keywords:  Geriatric Medicine; Primary Care; Public Health; Stroke Medicine

Mesh:

Substances:

Year:  2014        PMID: 24574366     DOI: 10.1136/eb-2013-101646

Source DB:  PubMed          Journal:  Evid Based Med        ISSN: 1356-5524


  2 in total

1.  What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process.

Authors:  Barbara Farrell; Corey Tsang; Lalitha Raman-Wilms; Hannah Irving; James Conklin; Kevin Pottie
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

2.  Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study.

Authors:  Andreas D Meid; Renate Quinzler; Julia Freigofas; Kai-Uwe Saum; Ben Schöttker; Bernd Holleczek; Dirk Heider; Hans-Helmut König; Hermann Brenner; Walter E Haefeli
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.